Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade ...
LAVAL, QC, April 21, 2026 /CNW/ - In recognition of AML World Awareness Day, Servier Canada is highlighting the progress made in precision medicine for Acute Myeloid Leukemia (AML). With TIBSOVO(R) ...
U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally BOSTON, May 28, 2025 /PRNewswire/ -- Servier today announced ...
Collaboration combines Servier’s CNS expertise and MiNA’s pioneering small activating RNA technology. MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first ...
French biopharma Servier has bought up Danish cancer biotech Symphogen as it looks to bolster its immuno-oncology pipeline. The deal, financial terms of which have not been made public, unusually, ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, and Servier, an independent international ...
A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of th ...
A Servier Pharmaceuticals drug designed to penetrate the brain to hit its targets is now FDA approved for treating two rare types of brain cancer. The FDA approval announced Tuesday covers the ...
International pharmaceutical group Servier has expanded its partnership with Google Cloud to accelerate the research and development (R&D) of pharmaceuticals. Servier and Google Cloud have entered ...
After cancer drug Tibsovo hit a hurdle in Europe while in the hands of former developer Agios Pharmaceuticals, Servier, the drug’s new owner, has been looking for a late-stage trial win to reach the ...
A Servier Pharmaceuticals drug acquired as part of a $1.8 billion deal has won an additional FDA approval as a treatment for a rare type of blood cancer carrying a specific mutation. The regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results